Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma.
D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000009:adverse effects / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*
D000873:Anthracenes; D009607:Nitrosourea Compounds; C031404:bisantrene; C018627:1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidinyl)-1-nitrosourea